Participants (P) | Intervention (I) | Comparison (C) | Outcomes (O) |
---|---|---|---|
Inclusion criteria | |||
Males and females of any age, ethnicity, socioeconomic status, geographic area, comorbidity or pregnancy status | Vitamin D2 and/or vitamin D3 supplementation, administered in any form (intravenous, intramuscular, or oral), alone or combined with other intervention/s, of any dosage, and for any duration | Placebo or usual care. Any other non-pharmacological interventions or pharmacological interventions | Inflammatory biomarkers including, but not limited to: all interleukins, all TNFα, TGF-β1, hs/CRP, MCP-1, ADMA, PAI-1, SAA, IFNγ, NFκB, MIF, ICAMs, fibrinogen, MMPs, adipocytokines: leptin, resistin, visfatin, adiponectin, omentin |
Exclusion criteria | |||
None | Studies without vitamin D supplementation | ||
Study type | Systematic reviews of RCTs and RCTs | ||
Language | No limit | ||
Year of publication | No limit |
ADMA, assymetric dimethylarginine; hsCRP, high sensitivity C reactive protein; ICAMs, intracelleular adhesion molecules; IFNγ, interferon γ; MCP-1, monocyte chemotactic protein 1; MIF, macrophage migration inhibitory factor; MMPs, matrix metalloproteinases; NFκB, nuclear factor κB; PAI-1, plasminogen activator inhibitor 1; RCT, randomised controlled trial; SAA, serum amyloid A; TGF-β1, tumour growth factor 1; TNFα, tumour necrosis factor α.